Dantari

Executive Summary

Dantari is a preclinical-stage biotechnology company developing a novel targeted drug delivery platform designed to enhance the therapeutic index of cancer drugs. Founded in 2019 and based in San Diego, the company has raised $47 million to advance its pipeline of antibody-drug conjugates (ADCs) and other targeted therapies. Its proprietary technology enables precise delivery of potent payloads to tumors while minimizing off-target toxicity, addressing a key challenge in oncology. Dantari's approach has the potential to improve efficacy and safety across multiple cancer indications, positioning it as a promising player in the ADC space. With a lean team of 1-50 employees and a focus on preclinical development, the company is poised to generate key data readouts that could unlock significant value. Investors should watch for progress toward IND-enabling studies and potential strategic partnerships as Dantari moves toward clinical trials.

Upcoming Catalysts (preview)

• Q3 2026Preclinical data presentation at major oncology conference70% success
• Q1 2027IND filing for lead ADC candidate60% success
• Q4 2026Series B financing round75% success